EP1455796A1 - Method for the treatment of bone disorders - Google Patents

Method for the treatment of bone disorders

Info

Publication number
EP1455796A1
EP1455796A1 EP20020795891 EP02795891A EP1455796A1 EP 1455796 A1 EP1455796 A1 EP 1455796A1 EP 20020795891 EP20020795891 EP 20020795891 EP 02795891 A EP02795891 A EP 02795891A EP 1455796 A1 EP1455796 A1 EP 1455796A1
Authority
EP
European Patent Office
Prior art keywords
bisphosphonate
dose
loading
bone
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP20020795891
Other languages
German (de)
English (en)
French (fr)
Inventor
Pamela Jean Schofield
Henry Van Den Berg
David Ernest Burgio
Arkadi Aaron Chines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23352430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1455796(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP1455796A1 publication Critical patent/EP1455796A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • This invention relates to methods of increasing bone mass and reduction of fractures for the treatment of osteoporosis and other bone metabolic disorders.
  • this invention relates to such methods of treatment by the administration of a loading dose of a bone-active phosphonate followed by a maintenance dosing regimen.
  • Osteoporosis can be generally defined as the reduction in the quantity of bone, or the atrophy of skeletal tissue due to an imbalance in the normal resorption/formation cycle of bone within the bone remodeling unit.
  • Primary and secondary osteoporosis are two types of osteoporosis: Primary and secondary.
  • Secondary osteoporosis is the result of an identifiable disease process or agent. For example, glucocorticoid steroids are known to induce osteoporosis.
  • Such primary osteoporosis includes postmenopausal osteoporosis, age-associated osteoporosis (affecting a majority of individuals over the age of 70 to 80) and idiopathic osteoporosis.
  • Bone fractures often occur, for example, in the hip and spine of women suffering from postmenopausal osteoporosis. Kyphosis (abnormally increased curvature of the thoracic spine) may also result. Although its etiology is not fully understood, there are many risk factors thought to be associated with osteoporosis. These include low body weight, low calcium intake, physical inactivity, and estrogen deficiency. Many compositions and methods are described for the "treatment" of osteoporosis. Many of these include the use of bisphosphonates or other bone-active phosphonates. See, for examples, J.Y.
  • Applicants have found, surprisingly, that the administration of a high dose of a bone- active phosphonate followed by a lower maintenance dose decreases bone turnover and increases bone mass at a faster rate leading to faster fracture reduction. This may be particularly useful in patients who experience high bone turnover, such as cancer and transplant patients.
  • the present invention provides methods of increasing bone mass and/or reducing fractures in a subject afflicted with bone loss.
  • the method comprises the steps of: (a) administering a loading dose of a bisphosphonate for a period of time of from about 7 to about 180 days, more preferably from about 14 to about 60 days, followed by (b) administering a continuous maintenance dose of a bisphosphonate.
  • the loading dose comprises a level of bisphosphonate of from about 2 to about 20 times, preferably from about 3 times to about 10 times, more preferably from about 3 times to about 6 times greater than the corresponding maintenance dose.
  • the loading dose is administered over a period of time from about 7 to about 180 days.
  • the loading dose is administered every day or ever other day whereas the maintenance dose may be administered every day, twice a week, weekly, bi-weekly, or monthly.
  • the methods of the present invention comprise the administration of a loading dose of a bone-active phosphonate and a maintenance dose of a bone-active phosphonate.
  • Specific compounds and compositions to be used in these processes must, accordingly, be pharmaceutically-acceptable. Definitions:
  • administering means any method which, in sound medical practice, delivers the actives used in this invention to the subject treated in such a manner so as to be effective in the building of bone.
  • the actives may be administered by any of a variety of known methods of administration, e.g., orally, dermatomucosally (for example, dermally, sublingually, intranasally, and rectally), parenterally (e.g., subcutaneous injection, intramuscular injection, intra-articular injection, intravenous injection), topically (transdermal) and inhalating.
  • specific modes of administration include, but are not limited to, oral, transdermal, mucosal, sublingual, intramuscular, intravenous, intrapertioneal, subcutaneous administration, and other topical application.
  • “Loading dose”, as used herein, means the dose initially administered to a patient.
  • the dose is an effective amount to achieve the desired results.
  • Loading period means the period of time in which the initial dose is administered to a subject.
  • Mainntenance dose means the dose administered to a subject following the loading period.
  • the dose is an effective amount to achieve the desired results.
  • Maintenance period means, means the period of time following the loading period in which the subject is continuously administered a dose of bisphosphonate at a dosage level lower than the loading dose.
  • Safe and effective amount means an amount large enough to significantly induce a positive modification in the symptoms and/or condition to be treated in a subject, but small enough to avoid serious adverse side effects, commensurate with a reasonable benefit/risk ratio.
  • the safe and effective amount will vary with such factors as the particular condition being treated, the age and physical condition of the patient, the duration of treatment, the nature of concurrent therapy, the specific dosage form to be used, and the dosage regimen employed.
  • the method of the present invention comprises the steps of
  • step (b) administering after step (a) a continuous maintenance dose of a bisphosphonate. wherein said loading dose is from about two (2) times to about twenty (20) times greater than said maintenance dose.
  • the loading dose period is comprised of a separate administration regimen for the bisphosphonate.
  • the bisphosphonate must be given with sufficient frequency in the loading dose period in order to achieve the physiological effect in the subject being treated.
  • an oral dosage unit of bisphosphonate is preferably administered every day of the loading period. It may be desirable to administer one type of bisphosphonate on some treatment days and another type on another treatment day.
  • a bisphosphonate must be given at least once every three months after the loading period.
  • a bisphosphonate may be given every day, every other day, twice a week, weekly, bi-weekly, once a month or every other month. It may be desirable to administer one type of bisphosphonate on some treatment days, and another type on another treatment day.
  • the specific period of time and the frequency of dosing which is sufficient to achieve an increase in the net skeletal mass of the subject may depend on a variety of factors. Such factors include, for example, the specific actives employed, the amount of actives administered, the mode of administration (i.e. oral or parenteral) the age and sex of the subject, the specific disorder to be treated, concomitant therapies employed, the general physical health of the subject, the extent of bone loss in the individual, and the nutritional habits of the individual.
  • the therapeutic regimen utilizing the methods of this invention are preferably continued for at least about twenty four months.
  • a therapeutic regimen may be continued indefinitely, according to sound medical practice.
  • a preferred method for the treatment of a bone disorder includes an initial diagnostic step, to determine the presence of the disorder.
  • a preferred method of this invention comprises the steps of performing a diagnostic on a subject for the detection of high bone turnover.
  • High bone turnover can be defined when the net bone turnover is elevated and bone resorption is greater than bone formation.
  • administering the actives according to the methods of this invention is then implemented.
  • Measurement of biochemical markers may be used to determine the rate of bone turnover. Bone remodeling may be confirmed by histomorphology.
  • Suitable diagnostics for the detection of established osteoporosis are also well known in the art. Such methods include the measurement of the radiodenisty of skeletal radiographs, quantitative computerized tomography, single energy photon abso ⁇ tiometry, and dual-energy photon abso ⁇ timoetry. Diagnostic techniques among those useful herein are described in W.A. Peck et al., Physician's Resource Manual on osteoporosis (1987), published by the National Osteoporosis Foundation (inco ⁇ orated by reference herein).
  • the bone-active phosphonate encompasses acid, salts, and derivatives thereof.
  • Nonlimiting examples of bisphosphonates useful herein include the following: l-hydroxy-2-(3-pyridinyl)-ethylidene-l,l-bisphosphonic acid (risedronate) as described in U.S. Pat. No. 5,583,122, to Benedict, et al, Dec. 10, 1996, which is inco ⁇ orated by reference herein in its entirety.
  • 4-amino-l-hydroxybutylidene-l,l-bisphosphonic acid (alendronic acid) as described in U.S. Pat. No. 4,621,077, to Rosini et al., Nov.
  • Preferred bisphosphonates are selected from the group consisting of risedronate, ibandronate, pamidronate, alendronate, cimadronate, tiludronate, zolendronate, clodronate, piridronate, pharmaceutically-acceptable salts thereof and mixtures thereof.
  • the amount of bisphosphonate to be administered depends upon its potency.
  • the potency of a particular bisphosphonate can be expressed in terms of its "LED” or "least effective dose", which is a minimum dose of bisphosphonate expressed in mg P/kg (milligrams phosphorus in the compound per kilogram weight of the subject) that is effective, by itself, to cause a significant inhibition of bone reso ⁇ tion.
  • the specific LEDs of the bisphosphonates will vary depending upon their chemical composition, and their method of administration (i.e., oral or parenteral). The lower the LED, the more potent the bisphosphonate and, generally, it is desirable to administer the high potency bisphosphonate in lower doses and on a fewer number of days.
  • the LEDs for oral dosing would be higher, depending upon the systemic abso ⁇ tion of the phosphonate. Typically, abso ⁇ tion from oral administration is from about 1% to about 10%. Thus, oral LEDs are typically about ten- to about one hundred-fold higher than the parenteral LEDs.
  • the bone-active phosphonate may be administered in any of a variety of pharmaceutically-acceptable compositions.
  • Such compositions may comprise an active and a pharmaceutically-acceptable carrier.
  • Pharmaceutically-acceptable carriers include solid or liquid filler diluents or encapsulating substances, and mixtures thereof, that are suitable for administration to a human or lower animal.
  • the term "compatible,” as used herein, means that the components of the pharmaceutical composition are capable of being commingled with the actives, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the pharmaceutical composition under ordinary use situations.
  • Pharmaceutically-acceptable carriers must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the subject being treated.
  • substances which can serve as pharmaceutical carriers are: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; stearic acid; magnesium stearate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; ppolyols such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol; agar; alginic acid; pyrogen-free water; isotonic saline; phosphate buffer solutions; wetting agents and lubricants such as sodium lauryl sulfate; coloring agents; flavoring agents; and preservatives.
  • sugars such as lactose, glucose and sucrose
  • starches such as corn
  • compositions of the present invention may be included in the pharmaceutically-acceptable carrier for use in the compositions of the present invention.
  • a pharmaceutically-acceptable carrier to be used in conjunction with the active is determined by the way the active is to administered. If the active is to be injected, the preferred pharmaceutical carrier is sterile water, physiological saline, or mixtures thereof. The pH of such parenteral composition is preferably adjusted to about 7.4.
  • Suitable pharmaceutically- acceptable carriers for topical application include those known in the art for use in creams, gels, tapes, patches, and similar topical delivery means.
  • the pharmaceutically-acceptable carrier employed in conjunction with the actives is used at a conscentration sufficient to provide a practical size to dosage relationship.
  • the pharmaceutically-acceptable carriers in total, may comprise from about 0.1% to about 99.9% by weight of the pharmaceutical compositions of the present invention, preferably from about 5% to about 80% and most preferably from about 10% to about 50%.
  • a preferred method of administering bisphosphonates is orally, in a unit-dosage form (i.e., a dosage form containing an amount of active suitable for administration in one single dose, according to sound medical practice).
  • Preferred unit dosage forms for bisphosphonate include tablets, capsules, suspensions, and solutions, comprising a safe and effective amount of active.
  • Pharmaceutically-acceptable carriers suitable for the preparation of unit dosage forms for oral administration are well known in the art. Their selection will depend on secondary considerations like taste, cost, shelf stability, which are not critical for the purposes of the present invention, and can be made without difficulty by a person skilled in the art.
  • oral unit dosage forms of risedronate for the loading dose comprise from about 15mg to about 50mg per day, more preferably from about 20 mg to about 40 mg per day and most preferably from about 25 mg to about 35 mg per day.
  • the oral unit dosage forms of the bone-active phosphonate for the maintenance dose preferably contains from about 2.5 to about 15 mg per day from about 5 to about 10.
  • the loading dose comprises from about 15 mg to about 70 mg per day. More preferably from about 20 mg to about 50 mg per day, and most preferably about 25 mg to about 40 mg per day.
  • Equivalent doses can be given every other day, twice a week, weekly, biweekly or monthly.
  • unit dosage forms for injectable bone active bisphosphonate include sterile solutions of water, physiological saline, or mixtures thereof. The pH of said solutions should be adjusted to about 7.4.
  • unit dosage forms of risedronate for the loading dose comprise from about from about 0.75 mg to about 15.0 mg per month and more preferably from about 1.5 mg to about 10 mg per month.
  • the unit dosage forms of the bone-active phosphonate for the maintenance dose preferably contains from about 0.75 mg to about 6 mg per month and more preferably from about 1.5 mg to about 3 mg per month. Equivalent dosage amounts may be given every two weeks, every month, every other month or every three months.
  • kits for conveniently and effectively implementing the methods of this invention comprise one or more unit doses of bone-active phosphonate for the loading period, one or more unit doses of bone-active phosphonate for the maintenance period, and a means for facilitating compliance with methods of this invention.
  • kits provide a convenient and effective means for assuring that the subject to be treated takes the appropriate active in the correct dosage in the correct manner.
  • the compliance means of such kits includes any means which facilitates administering the actives according to a method of this invention.
  • Such compliance means includes, instructions, packaging, and dispensing means, and combinations thereof. Examples of packaging and dispensing means are well known in the art, including those described in U.S. Pat. No. 4,761,406, Flora et al., issued Aug. 2, 1988; and U.S. Patent 4,812,311, Uchtman, issued Mar. 14, 1989, all incorporated by reference herein.
  • a female patient weighing approximately 60 kg and diagnosed with postmenopausal osteoporosis is treated by a method of this invention. Specifically for thirty days the patient is given 30 mg per day of risedronate orally. Immediately following, the patient is given 35 mg per week of risedronate orally for two years. A biopsy of iliac crest bone is taken at two years and reveals an increase in mean wall thickness of the remodeling units compared to her baseline biopsy.
  • a male weighing approximately 70 kg diagnosed with prostrate cancer and high bone turnover is treated by a method of this invention. Specifically each day for fourteen days the patient takes 35 mg of alendronate per day. At the end of the period, the patient then takes a maintenance dose of 70 mg per week of alendronate orally for one year.
  • a female weighing about 58 kg is diagnosed with glucocorticoid-induced osteoporosis.
  • the subject is then treated by a method of this invention. Specifically the subject is given 30 mg risedronate orally per day for a period of 30 days. At that time, the dose is switched to the maintenance dose of 35 mg orally every two weeks for three years.
  • a male patient weighting approximately 67 kg is given intravenously; a total of 9 mg divided equally into two weekly doses (4.5 mg per week on days 1 and 8) of risedronate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP20020795891 2001-12-21 2002-12-16 Method for the treatment of bone disorders Ceased EP1455796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34487501P 2001-12-21 2001-12-21
US344875P 2001-12-21
PCT/US2002/040234 WO2003055496A1 (en) 2001-12-21 2002-12-16 Method for the treatment of bone disorders

Publications (1)

Publication Number Publication Date
EP1455796A1 true EP1455796A1 (en) 2004-09-15

Family

ID=23352430

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20020795891 Ceased EP1455796A1 (en) 2001-12-21 2002-12-16 Method for the treatment of bone disorders

Country Status (24)

Country Link
US (5) US20030118634A1 (sk)
EP (1) EP1455796A1 (sk)
JP (1) JP2005514400A (sk)
KR (1) KR100638122B1 (sk)
CN (1) CN100479823C (sk)
AR (1) AR038041A1 (sk)
AU (1) AU2002360619B2 (sk)
CA (1) CA2469779C (sk)
CZ (1) CZ2004690A3 (sk)
HK (1) HK1087039A1 (sk)
HU (1) HUP0402267A3 (sk)
IL (2) IL162053A0 (sk)
MA (1) MA27157A1 (sk)
MX (1) MXPA04006027A (sk)
MY (1) MY147886A (sk)
NO (1) NO340249B1 (sk)
NZ (1) NZ532994A (sk)
PE (1) PE20030743A1 (sk)
PL (1) PL371264A1 (sk)
RU (1) RU2294203C2 (sk)
SK (1) SK2532004A3 (sk)
TW (1) TWI349553B (sk)
WO (1) WO2003055496A1 (sk)
ZA (1) ZA200404007B (sk)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006027A (es) * 2001-12-21 2004-09-27 Procter & Gamble Metodo para el tratamiento de trastornos de los huesos.
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
JP4427453B2 (ja) * 2002-12-20 2010-03-10 エフ．ホフマン−ラ ロシュ アーゲー 高用量イバンドロネート製剤
KR101388777B1 (ko) * 2004-05-24 2014-04-23 워너 칠콧 컴퍼니 엘엘씨 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) * 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
EP0333082A3 (en) * 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
CA1336328C (en) * 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5018651A (en) * 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
TW237386B (sk) * 1992-04-15 1995-01-01 Ciba Geigy
HUT72061A (en) * 1992-05-29 1996-03-28 Procter & Gamble Pharma Quaternary nitrogen-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism as well as dental calculus and plaque, and pharmaceutical preparations containing them
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
DK0650361T3 (da) * 1992-06-30 1999-06-23 Procter & Gamble Pharma Sammensætninger til behandling af arthritis, hvilke sammensætninger indeholder phosphonater og NSAID'er
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
WO1996040873A1 (de) * 1995-06-07 1996-12-19 Co.Don Gmbh Gesellschaft Für Molekulare Medizin Und Biotechnologie Standardisierte, primäre osteoblastenzellkulturen aus osteoporotischen patienten und deren verwendung zur osteoporosediagnose und zur testung potentieller osteoporose-therapeutika
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
WO1999067809A1 (en) * 1998-06-24 1999-12-29 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
TR200101546T2 (tr) * 1998-12-04 2001-11-21 Roche Diagnostics Gmbh İç-protezlerde kemik entegrasyonunu iyileştirmek üzere ibandronat kullanılması.
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
WO2002005786A1 (fr) * 2000-07-17 2002-01-24 Yamanouchi Pharmaceutical Co., Ltd. Composition pharmaceutique a absorbabilite per os amelioree
AU2001272916A1 (en) * 2000-07-19 2002-02-05 Eli Lilly And Company Method for enhancing bone mineral density gain by administration of raloxifene
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
DK1372669T3 (da) * 2001-01-23 2005-10-17 Gador Sa Bisphosphonatholding sammensætning til forebyggelse og/eller behandling af metaboliske knoglesygdomme, fremgangsmåde til fremstilling af sådanne sammensætninger og anvendelse deraf
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
DK1365769T3 (da) * 2001-02-06 2011-05-16 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Lægemiddel til behandling af osteonekrose og til behandling af patienter med risiko for at udvikle osteonekrose
AU2002254082B2 (en) * 2001-03-01 2007-05-24 Emisphere Technologies, Inc. Compositions for delivering bisphosphonates
US6838584B2 (en) * 2001-05-10 2005-01-04 Merck & Co., Inc. Estrogen receptor modulators
WO2003051373A1 (en) * 2001-12-13 2003-06-26 Merck & Co., Inc. Liquid bisphosphonate formulations for bone disorders
MXPA04006027A (es) * 2001-12-21 2004-09-27 Procter & Gamble Metodo para el tratamiento de trastornos de los huesos.
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ETHEL S. SIRIS ET AL: "Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 13, no. 6, 1 June 1998 (1998-06-01), pages 1032 - 1038, XP055177312, ISSN: 0884-0431, DOI: 10.1359/jbmr.1998.13.6.1032 *
ZEGELS B ET AL: "Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis", BONE, PERGAMON PRESS., OXFORD, GB, vol. 28, no. 1, 1 January 2001 (2001-01-01), pages 108 - 112, XP027527569, ISSN: 8756-3282, [retrieved on 20010101] *

Also Published As

Publication number Publication date
HUP0402267A2 (hu) 2005-02-28
PL371264A1 (en) 2005-06-13
KR100638122B1 (ko) 2006-10-24
US20070166237A1 (en) 2007-07-19
CN100479823C (zh) 2009-04-22
KR20040065283A (ko) 2004-07-21
CA2469779A1 (en) 2003-07-10
MY147886A (en) 2013-01-31
CZ2004690A3 (cs) 2004-09-15
WO2003055496A1 (en) 2003-07-10
MA27157A1 (fr) 2005-01-03
HK1087039A1 (en) 2006-10-06
RU2004122433A (ru) 2005-03-10
MXPA04006027A (es) 2004-09-27
US20080214505A1 (en) 2008-09-04
CN1723024A (zh) 2006-01-18
PE20030743A1 (es) 2003-10-22
AU2002360619A1 (en) 2003-07-15
AR038041A1 (es) 2004-12-22
ZA200404007B (en) 2005-07-27
SK2532004A3 (en) 2004-11-03
IL162053A0 (en) 2005-11-20
HUP0402267A3 (en) 2007-05-29
US20080261924A1 (en) 2008-10-23
IL162053A (en) 2009-09-22
RU2294203C2 (ru) 2007-02-27
TW200301704A (en) 2003-07-16
NO20043113L (no) 2004-09-01
TWI349553B (en) 2011-10-01
NO340249B1 (no) 2017-03-27
CA2469779C (en) 2008-02-12
US20080260827A1 (en) 2008-10-23
US20030118634A1 (en) 2003-06-26
JP2005514400A (ja) 2005-05-19
NZ532994A (en) 2008-05-30
AU2002360619B2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
US5366965A (en) Regimen for treatment or prophylaxis of osteoporosis
AU663348B2 (en) Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone
Harris et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women
US6372728B1 (en) Formulation for treatment of osteoporosis
US20080261924A1 (en) Method for the treatment of bone disorders
JP5910698B2 (ja) リセドロネート組成物およびその使用方法
EP0573604B1 (en) Methods for the treatment of osteoporosis
US20040097468A1 (en) Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
Gangji et al. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures
Reid Steroid-induced osteoporosis.
NZ250293A (en) Fracture treatment using methanebisphosphonic acid derivatives and pharmaceutical compositions
EP0804202A1 (en) Estrogens and parathyroid hormone for treating osteoporosis
Doga et al. Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis
Jarvis et al. Bisphosphonates for osteoporosis prevention and treatment
WO1997012620A1 (en) Method and composition for treatment of osteoporosis
US20040014729A1 (en) Use of estramustine phosphate in the treatment of bone metastasis
Oehadian The management of bone metastases: role of bisphosphonate
Werner et al. Paget’s disease and bisphosphonates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VAN DEN BERG, HENRY

Inventor name: BURGIO, DAVID, ERNEST

Inventor name: CHINES, ARKADI, AARON

Inventor name: SCHOFIELD, PAMELA, JEAN

17Q First examination report despatched

Effective date: 20090220

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WARNER CHILCOTT COMPANY, LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WARNER CHILCOTT COMPANY, LLC

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20201207